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Abstract. Voltage-dependent K+ channels (Kv) are involved 
in the proliferation and differentiation of mammalian cells, 
since Kv antagonists impair cell cycle progression. Although 
myofibers are terminally differentiated, some myoblasts may 
re-enter the cell cycle and proliferate. Since Kv1.3 and Kv1.5 
expression is remodeled during tumorigenesis and is involved 
in smooth muscle proliferation, the purpose of this study 
was to analyze the expression of Kv1.3 and Kv1.5 in smooth 
muscle neoplasms. In the present study, we examined human 
samples of smooth muscle tumors together with healthy speci-
mens. Thus, leiomyoma (LM) and leiomyosarcoma (LMS) 
tumors were analyzed. Results showed that Kv1.3 was poorly 
expressed in the healthy muscle and indolent LM specimens, 
whereas aggressive LMS showed high levels of Kv1.3 expres-
sion. Kv1.5 staining was correlated with malignancy. The 
findings show a remodeling of Kv1.3 and Kv1.5 in human 
smooth muscle sarcoma. A correlation of Kv1.3 and Kv1.5 
expression with tumor aggressiveness was observed. Thus, 
our results indicate Kv1.5 and Kv1.3 as potential tumorigenic 
targets for aggressive human LMS.
Introduction
Voltage-dependent potassium channels (Kv) contribute to 
the myogenic regulation of vascular tone (1). In addition, Kv 
channels act in the cell cycle progression and differentiation of 
smooth muscle cells (2,3). In this context, Kv channels govern 
cell proliferation by controlling specific checkpoints during the 
cell cycle that are crucial for further cycle progression (4-7). 
During the G1/S phase of the cell cycle a temporary hyperpo-
larization occurs, in which Kv channels are involved (8). The 
voltage-dependent Kv1.3 and Kv1.5 channels are involved 
in cell proliferation, and expression remodeling has been 
described during neoplastic growth (5,9). A number of tissues, 
such as brain, muscle and the immune system, co-express the 
two channels (10-12). Kv1.3 abundance is generally down-
regulated, whereas Kv1.5 expression is enhanced in several 
types of human cancer (5,9,13).
Kv1.3 and Kv1.5 increase during myoblast prolif-
eration (11). Kv1.5 is the main subunit in skeletal myoblasts, 
whereas Kv1.3 is critical in smooth muscle (2,3). Thus, Kv1.5 
exhibits a cycle-dependent regulation in skeletal muscle 
myoblasts (11) and Kv1.3, which controls proliferation in 
leukocytes (14,15), is also involved in vascular cell prolifera-
tion and migration (2,3). In a preliminary report, it was noted 
that Kv1.3 and Kv1.5 undergo remodeling in human skeletal 
muscle sarcomas (13), which was recently demonstrated in 
depth (16), whereas there are no studies addressing Kv1.3 and 
Kv1.5 during neoplastic smooth muscle proliferation. The 
aim of the present study was to investigate, for the first time, 
the expression of Kv1.3 and Kv1.5 in human smooth muscle 
neoplasms. Leiomyoma (LM) and leiomyosarcoma (LMS) are 
benign and malignant soft tissue neoplasms, respectively, that 
arise from smooth muscle cells. LM is the most common type 
of uterine neoplasm occurring in women older than 35 years. 
Retroperitoneal LMS, a common primary retroperitoneal 
neoplasm, arises from smooth muscle within arteries, veins 
or the bowel.
In the present study, we observed a positive correlation 
between the malignancy of the smooth muscle neoplasm and 
the expression of Kv1.3 and Kv1.5. The results were notable for 
Kv1.3, which seems to be crucial in smooth myoblasts (2,3). 
The results indicate that Kv1.5 and Kv1.3 are potential tumori-
genic targets for aggressive LMS.
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Materials and methods
Patients, tissue characteristics and sample processing. A total 
of 6 smooth muscle tumor samples, 3 LM samples and 3 LMS 
samples were obtained from the Department of Pathology 
of Vall d'Hebron University Hospital and the Department of 
Pathology of Bellvitge Hospital (Barcelona, Spain) between 
2008 and 2009. A summary of patient and sample information 
is shown in Table I. Four non-tumoral uterine smooth muscle 
samples were added to the series as controls. Patients were 
informed and gave their consent for sample collection. The 
research investigations were approved by the University and 
the hospital's ethics committee.
Control and tumor samples were fixed in neutral formalin 
and embedded in paraffin for immunohistochemistry. Blinded 
diagnosis was performed independently by two pathologists 
using light microscopy and conventional hematoxylin and 
eosin staining. Tissue microarrays were constructed, including 
3 cores of 2-mm diameter from each case; two cores were 
from the central area of the tumor and the third was obtained 
from the invasive front. The results from representative cores 
were recorded.
For LMS, markers such as smooth-muscle actin, vimentin 
and desmin were used. LM was diagnosed with simple hema-
toxylin and eosin staining and light microscopy evaluation.
Antibodies and immunohistochemistry. Immunohistochemical 
staining using the avidin-biotin-peroxidase technique was 
performed for each antibody. Tissue microarrays were generated 
on poly-L-lysine-coated glass slides. Sections were deparaf-
finized in xylene and rehydrated in graded alcohol. For antigen 
retrieval, the microarrays were heated either in a pressure cooker 
in 10 mM citric acid monohydrate, pH 6.0, for 5 min (Kv1.5), 
or in 10 mM citric acid monohydrate, pH 9.0 for 40 min in a 
98˚C water bath (Kv1.3). Endogenous peroxidase was blocked 
by incubating the sections in 3% hydrogen peroxidase blocking 
solution for 10 min. Arrays were immunoblotted with anti-Kv1.3 
(1:70) and anti-Kv1.5 (1:100) polyclonal antibodies (Alomone) 
for 1 h, followed by an HRP-labeled polymer anti-rabbit 
antibody (DakoCytomation, Glostrup, Denmark) for 30 min. 
Immunohistochemical detection was performed with the 
EnVision system (DakoCytomation). The samples were coun-
terstained with hematoxylin, dehydrated and mounted. Negative 
controls were prepared in all cases by omitting the primary 
antibody as described in previous studies (16,17). Antibody 
staining has been extensively validated previously (13,16,17). 
Additionally, as previously reported, but not yet understood, 
some Kv1.5 nuclear staining was observed (13,16-18); therefore, 
only cytoplasm staining was evaluated.
Immunohistochemistry evaluation and statistical analysis. 
Cases were evaluated by pathologists who assessed the 
percentage of positively stained cells and semi-quantitatively 
described the staining intensity. Kv1.3 and Kv1.5 staining was 
evaluated by calculating a histoscore (Hscore). The Hscore = 
(1 x % weakly stained cells) + (2 x % moderately stained cells) 
+ (3 x % strongly stained cells), with results ranging from 
0 to 300, as previously described (16,19). Weakly stained cells 
were marked (+), moderately stained cells (++) and strongly 
stained cells (+++). In randomly chosen cases, the immuno-
staining was performed in complete tissue sections to evaluate 
the consistency of the results.
Values were expressed as the means ± SEM and analyzed 
by Student's t-test. P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
Immunohistochemistry of Kv1.3 and Kv1.5 in smooth muscle 
tumors. In vascular smooth muscle (VSMC), Kv1.3 and Kv1.5 
expression remodels during VSMC proliferation (2,3). Kv1.5 
downregulates, whereas Kv1.3 increases (2). However, the 
expression of Kv1.3 and Kv1.5 in other smooth muscle tissues, 
such as the bladder or uterus, is under debate (3). Since the 
two channels are involved in cell proliferation, we investigated 
the expression of Kv1.3 and Kv1.5 in human smooth muscle 
neoplasms. Two types of human smooth muscle tumors were 
studied: an indolent uterus smooth muscle LM and an aggres-
sive retroperitoneal LMS. Healthy specimen counterparts 
were also included.
Fig. 1 shows representative images of Kv1.3 and Kv1.5 
staining in LM and LMS compared with healthy myometrial 
samples. Remodeling of Kv1.3 was detected in uterine smooth 
muscle biopsies. Kv1.3 staining in the control sample (Fig. 1A) 
was faint (+, 90%) and extremely low (-/+, 50%) in the less 
aggressive LM (Fig. 3C). However, the expression of Kv1.3 
was clearly notable (++, 100%) in LMS (Fig. 3E). By contrast, 
Kv1.5 staining was almost absent (-, 98%) in the healthy smooth 
muscle (Fig. 1B). A heterogeneous faint Kv1.5 expression was 
detected (+, 50%) in LM samples (Fig. 1D), whereas LMS 
showed a homogenous but poor expression (-/+, 100%) of 
Kv1.5 (Fig. 1F).
Histoscore evaluation for smooth muscle tumors. Hscore has 
been validated as a semi-quantitative analysis for evaluation 
of the protein expression with immunohistochemistry (16,19). 
Therefore, to analyze Kv1.3 and Kv1.5 staining, an Hscore 
was calculated as described in Materials and methods (Fig. 2). 
Fig. 2A shows a graphical representation of the Hscore for 
Table I. Sample characteristics and diagnostic markers.
Diagnosis n Mean age Gender Diagnostic method/markers
Retroperitoneal leiomyosarcoma (LMS) 3 67 M Vimentin, desmin, smooth muscle actin
Uterine leiomyoma (LM) 3 43 F Blinded morphometry
M, male; F, female.
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individual samples of smooth muscle tumors and healthy 
specimens. Fig. 2B shows the means ± SEM for different 
groups. Kv1.3 appeared to be the dominant channel in smooth 
muscle tumors. The expression of Kv1.3 in healthy smooth 
muscle was low or null, similar to that of the indolent LM, but 
its expression was notably increased in LMS (Fig. 2A and B). 
Kv1.3 expression in this aggressive sarcoma was 4-fold higher 
than that in the control samples (Fig. 2B), whereas Kv1.5 
staining was slightly increased in the two types of tumors 
(Fig. 2A and B).
Thus, although the expression of the two channels showed 
a similar correlation with malignancy (Fig. 2B), the results 
were clear for Kv1.3. Kv1.3 staining was similar in the indolent 
LM and healthy specimens, but was significantly elevated in 
the aggressive LMS. A similar pattern was observed for Kv1.5, 
although to a lesser extent.
Figure 1. Representative images of Kv1.3 and Kv1.5 immunostaining in smooth muscle tumor and healthy samples. (A and B) SM, uterine smooth muscle 
control. (C and D) LM, leiomyoma. (E and F) LMS, leiomyosarcoma. (A, C and E) Kv1.3. (B, D and F) Kv1.5.
Figure 2. Graphical representation of the histoscore calculated from Kv1.3 and Kv1.5 immunohistochemistry. (A) Kv1.3 and Kv1.5 expression in smooth muscle 
tumor and control samples. SM1-SM4, smooth muscle control. LM1-LM3, leiomyoma samples. LMS1-LMS3, leiomyosarcoma samples. White bars, Kv1.3; 
gray bars, Kv1.5. (B) Histoscore mean values ± SEM for Kv1.3 and Kv1.5 in smooth muscle tumors and control samples. White bar, control smooth muscle 
tissue (SM); light gray bar, leiomyoma (LM); black bar, leiomyosarcoma (LMS). *p<0.05 and **p<0.001 (Student's t-test). 
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Discussion
Kv channels, which control cell excitability in muscle, also 
contribute to myoblast proliferation (2,11). In this study, we 
have shown for the first time that the expression of Kv1.3 and 
Kv1.5 increased in smooth muscle tumorigenesis in a close 
correlation with malignancy. Kv1.3, which governs smooth 
muscle proliferation and migration (2,3), increased notably in 
LMS. In addition, Kv1.5 expression, which steadily increases 
with aggressiveness, was shown to be almost absent in human 
myometrial smooth muscle.
Kv1.5 is involved in skeletal muscle cell proliferation (11). 
Unlike Kv1.5, Kv1.3 governs macrophage cell growth (14), 
but plays no substantial role in skeletal myoblast prolife-
ration (11). In a recent study, we observed a correlation of 
Kv1.3 and Kv1.5 expression with tumor malignancy in rhab-
domyosarcomas (16). However, Kv1.3 staining revealed no 
major differences between tumors and healthy samples (16). 
Therefore, the role of Kv1.3 in skeletal myoblasts is uncertain. 
By contrast, Kv1.3 action on smooth muscle proliferation 
seems defined and, similar to leukocytes, recent evidence 
supports the involvement of Kv1.3 in vascular smooth muscle 
cell (VMSC) proliferation and migration (2,3).
Kv1.3 and Kv1.5 remodel in a large variety of human 
cancers (13). In addition, their expression correlates with rhab-
domyosarcoma aggressiveness (16). Much evidence supports 
a role for ion channels in cancer development, progression 
and metastasis, and Kv1.3 and Kv1.5 may serve as potential 
biomarkers and/or anti-cancer therapeutic targets (9). In our 
study, aggressive LMS exhibited Kv1.3 staining higher than 
that of indolent LM and control smooth muscle biopsies. In 
addition, Kv1.5 expression also increased in LMS. Both results 
are in agreement with previous reports demonstrating that 
Kv1.5 and Kv1.3 play a role in skeletal and smooth muscle cell 
proliferation (2,3,11).
VSMCs are responsible for the correct contraction and 
dilatation of blood vessels, which play a crucial role in 
hypertension. In addition, VSMCs are capable of changing 
their phenotype from contractile to proliferative (2,3). This is 
an important feature during wound healing, but it may also 
become pathological in neointimal hyperplasia. The expression 
pattern of Kv undergoes a marked change during this switch. 
While contractile murine VSMCs express almost all isoforms 
of the Kv1 family (Kv1.1 - Kv1.6), which control the vascular 
tone (3,20-22), proliferating cells lose the expression of the 
majority of the VSMCs, solely upregulating Kv1.3 (2,3). Thus, 
proliferating human vein smooth muscle cells undergoing 
intimal neoplasia express high levels of Kv1.3, which further 
supports a putative role in VSMC proliferation. In this situa-
tion, Kv1.3 blockers inhibit growth and migration of venous 
cells (2,3). In this context, our results support findings of 
previous reports, suggesting Kv1.3 as a potential target for 
pathologies involving the excessive proliferation of smooth 
muscle cells (2,3).
In conclusion, these results demonstrate for the first 
time that Kv1.3 and Kv1.5 are specifically remodeled during 
smooth muscle carcinogenesis. A notable Kv1.3 expression is 
associated with smooth muscle cancer aggressiveness and a 
correlation of Kv1.5 expression is observed with tumorigen-
esis. Furthermore, our study argues in favor of Kv channels as 
potential therapeutic targets in pathologies involving excessive 
cell proliferation.
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